ELCIN: elacestrant in CDK4/6 inhibitor-naïve ER+/HER2- metastatic breast cancer
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in pre-treated patients with ER+/HER2- metastatic breast cancer. Based on the findings of the EMERALD trial (NCT03778931), which demonstrated significant progression-free survival benefits for elacestrant, the ELCIN trial further explores its efficacy and safety. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
